Additionally, the PFS of aumolertinib was significantly extended compared with that of gefitinib (19.3 vs. 9.9 months, hazard ratio [HR] ​= ​0.46, P < 0.0001) in treatment-naïve EGFR-sensitizing-mutated NSCLC.26 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.